Innovation
1 patent family — focus: Human necessities; filing pace steady. Cited 37 times.
| Year | Filings |
|---|---|
| 2022 | 1 |
| 2023 | 1 |
| 2024 | 1 |
| 2025 | 1 |
Investor mix
1 investor on record.
| Investor type | Count | Share |
|---|---|---|
| Other / undisclosed | 1 | 100% |
Developer of novel therapies for venous disease prevention and treatment. This company leverages molecular insights to create improved therapies for patients. Their focus includes preventing venous thromboembolism (VTE),
1 patent family — focus: Human necessities; filing pace steady. Cited 37 times.
| Year | Filings |
|---|---|
| 2022 | 1 |
| 2023 | 1 |
| 2024 | 1 |
| 2025 | 1 |
1 investor on record.
| Investor type | Count | Share |
|---|---|---|
| Other / undisclosed | 1 | 100% |